Actavis, Inc. Press Releases

ACT 
$257.09
*  
2.89
1.14%
Get ACT Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading ACT now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension
12/24/2014 1:15:00 PM - PR Newswire


Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
12/24/2014 8:00:00 AM - PR Newswire
▲1.56 % Price Change since this news event. The Volume Ratio is 0.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer
12/22/2014 9:24:00 AM - PR Newswire
▼-3.03 % Price Change since this news event. The Volume Ratio is 0.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference
12/22/2014 9:00:00 AM - PR Newswire
▼-3.03 % Price Change since this news event. The Volume Ratio is 0.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults
12/19/2014 4:15:00 PM - PR Newswire
▼-3.13 % Price Change since this news event. The Volume Ratio is 0.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
12/19/2014 9:00:00 AM - PR Newswire
▼-2.43 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition
12/16/2014 7:30:00 AM - PR Newswire
▼-2.25 % Price Change since this news event. The Volume Ratio is 1.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR
12/15/2014 3:11:00 PM - PR Newswire
▼-2.38 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR
12/11/2014 6:52:00 PM - PR Newswire
▼-1.21 % Price Change since this news event. The Volume Ratio is 1.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Launches Generic Version of Celebrex®
12/10/2014 9:28:00 AM - PR Newswire
▼-2.52 % Price Change since this news event. The Volume Ratio is 1.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Anti-Infective Advisory Committee Recommends Approval Of Actavis'' Ceftazidime-Avibactam
12/5/2014 4:46:00 PM - PR Newswire
▼-3.37 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam
12/5/2014 4:46:00 PM - PR Newswire
▼-3.37 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Launches Generic Version of Intuniv®
12/1/2014 4:05:00 PM - PR Newswire
▼-2.27 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
11/21/2014 6:27:00 PM - Business Wire


ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
11/21/2014 6:27:00 PM - Business Wire


Fitch Affirms Actavis at ''BBB-'' on Allergan Acquisition Announcement; Outlook Stable
11/17/2014 12:20:00 PM - Business Wire


ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
11/17/2014 10:32:00 AM - PR Newswire


Valeant Comments On Allergan Announcement
11/17/2014 9:29:00 AM - PR Newswire


Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue
11/17/2014 9:15:00 AM - PR Newswire


Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
11/17/2014 8:00:00 AM - PR Newswire


Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients
11/13/2014 8:00:00 AM - PR Newswire
▲7.12 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Names Maria Teresa Hilado Chief Financial Officer
11/10/2014 4:15:00 PM - PR Newswire
▲4.62 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
11/5/2014 6:45:00 AM - PR Newswire
▲4.72 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
11/5/2014 6:30:00 AM - PR Newswire
▲4.72 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
10/31/2014 4:15:00 PM - PR Newswire
▲5.91 % Price Change since this news event. The Volume Ratio is 1.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day